HomeInsightsStock Comparison

Aspira Pathlab Diagnostics Ltd vs Take Ltd Stock Comparison

Aspira Pathlab Diagnostics Ltd vs Take Ltd Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

  • The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20 . The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Take Solutions Ltd changed from 2.6 on March 2025 to 54.3 on March 2026 . This represents a CAGR of 83.64% over 5 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Take Solutions Ltd changed from ₹ 306.22 crore on March 2024 to ₹ 586.26 crore on March 2026 . This represents a CAGR of 11.43% over 6 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Take Solutions Ltd for the Jun '26 is ₹ 31.7 crore as compare to the Mar '26 revenue of ₹ 59.37 crore. This represent the decline of -46.61% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Take Solutions Ltd for the Jun '26 is ₹ 1.06 crore as compare to the Mar '26 ebitda of ₹ 4.36 crore. This represent the decline of -75.69% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Take Solutions Ltd changed from ₹ -3.75 crore to ₹ 1.06 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Take Solutions Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Aspira Pathlab & Diagnostics Ltd

  • Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
  • ASDL is a leading pathology specialist, with Pan-India presence.
  • It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
  • The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
  • Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

About Take Solutions Ltd

  • Take Solutions Limited was incorporated on December 20, 2000.
  • The Company has been promoted by a team of domain experts in the supply chain management sector of the software industry. TAKE Solutions delivers domain-intensive services and solutions in Life Sciences, Software and Information Technology.
  • In the fast-growing Life Sciences space, the Company offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise.
  • Its global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers.
  • As of March 31, 2025, TAKE Solutions Pte Ltd owned 52.90% of the Company's equity share capital and has the ability to control its operating and financial policies. In Supply Chain Management, TAKE through its subsidiaries focuses on niche engineering services, supply chain collaboration and product re-engineering.

FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Take Solutions Ltd

Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Take Solutions Ltd?

Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Take Solutions Ltd is 161 Cr

What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Take Solutions Ltd?

The stock performance of Aspira Pathlab & Diagnostics Ltd and Take Solutions Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Take Solutions Ltd?

As of October 25, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Take Solutions Ltd stock price is INR ₹10.93.

How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Take Solutions Ltd compare?

To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Take Solutions Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions